ProjectFOR2314 TP11 – HECT ligase inhibition for cancer therapy

Basic data

FOR2314 TP11
HECT ligase inhibition for cancer therapy
01/09/2018 to 31/08/2021
Abstract / short description:
The central goal of this research program is to lay the ground for harnessing the activities of HECT-type ubiquitin ligases in cancer-therapy. With a particular focus on HUWE1, we will pursue two specific aims:

1. Rational optimization of small-molecule HUWE1 inhibitors
Building on two hit compounds from a previous high-throughput screen, we aim to develop high-affinity, specific inhibitors of HUWE1 that are suitable for in vivo applications. By defining the mechanisms and structural determinants of specificity of synthesized compounds for HUWE1 we will provide unprecedented insights into the druggability of HECT E3 enzymes in general.

Involved staff


Faculty of Science
University of Tübingen
Pharmaceutical Institute
Department of Pharmacy and Biochemistry, Faculty of Science
Baden-Württemberg Center for Brazil and Latin America
Branch offices and other central facilities
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions

Contact persons

Faculty of Medicine
University of Tübingen

Local organizational units

Pharmaceutical Institute
Department of Pharmacy and Biochemistry
Faculty of Science


Bonn, Nordrhein-Westfalen, Germany

will be deleted permanently. This cannot be undone.